Annual CFF
$2.03 M
+$1.99 M+6061.70%
December 31, 2023
Summary
- As of February 7, 2025, MNPR annual cash flow from financing activities is $2.03 million, with the most recent change of +$1.99 million (+6061.70%) on December 31, 2023.
- During the last 3 years, MNPR annual CFF has fallen by -$6.15 million (-75.22%).
- MNPR annual CFF is now -81.37% below its all-time high of $10.88 million, reached on December 31, 2021.
Performance
MNPR Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
-$16.50 K
-$6600.00-66.67%
September 30, 2024
Summary
- As of February 7, 2025, MNPR quarterly cash flow from financing activities is -$16.50 thousand, with the most recent change of -$6600.00 (-66.67%) on September 30, 2024.
- Over the past year, MNPR quarterly CFF has dropped by -$3.20 million (-100.52%).
- MNPR quarterly CFF is now -100.15% below its all-time high of $10.92 million, reached on March 31, 2021.
Performance
MNPR Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$3.49 M
-$263.20 K-7.01%
September 30, 2024
Summary
- As of February 7, 2025, MNPR TTM cash flow from financing activities is $3.49 million, with the most recent change of -$263.20 thousand (-7.01%) on September 30, 2024.
- Over the past year, MNPR TTM CFF has dropped by -$914.30 thousand (-20.76%).
- MNPR TTM CFF is now -81.23% below its all-time high of $18.60 million, reached on March 31, 2021.
Performance
MNPR TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
MNPR Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +6061.7% | -100.5% | -20.8% |
| 3 y3 years | -75.2% | -65.0% | -67.9% |
| 5 y5 years | +1082.7% | -100.2% | -81.2% |
MNPR Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -81.4% | +6061.7% | -100.5% | +74.8% | -67.9% | +3169.5% |
| 5 y | 5-year | -81.4% | +6061.7% | -100.2% | +74.8% | -81.2% | +3169.5% |
| alltime | all time | -81.4% | +1082.7% | -100.2% | +92.0% | -81.2% | +1519.8% |
Monopar Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$16.50 K(+66.7%) | $3.49 M(-7.0%) |
| Jun 2024 | - | -$9900.00(-100.3%) | $3.75 M(-14.8%) |
| Mar 2024 | - | $3.18 M(+851.2%) | $4.40 M(+117.3%) |
| Dec 2023 | $2.03 M(+6061.7%) | $334.50 K(+35.6%) | $2.03 M(+10.7%) |
| Sep 2023 | - | $246.70 K(-61.5%) | $1.83 M(+17.3%) |
| Jun 2023 | - | $641.20 K(-20.3%) | $1.56 M(+82.7%) |
| Mar 2023 | - | $804.80 K(+480.2%) | $854.30 K(+2504.6%) |
| Dec 2022 | $32.90 K(-99.7%) | $138.70 K(-685.2%) | $32.80 K(-128.8%) |
| Sep 2022 | - | -$23.70 K(-63.8%) | -$113.70 K(+13.7%) |
| Jun 2022 | - | -$65.50 K(+292.2%) | -$100.00 K(+70.9%) |
| Mar 2022 | - | -$16.70 K(+114.1%) | -$58.50 K(-100.5%) |
| Dec 2021 | $10.88 M(+33.0%) | -$7800.00(-22.0%) | $10.88 M(-0.0%) |
| Sep 2021 | - | -$10.00 K(-58.3%) | $10.88 M(-38.3%) |
| Jun 2021 | - | -$24.00 K(-100.2%) | $17.63 M(-5.2%) |
| Mar 2021 | - | $10.92 M(<-9900.0%) | $18.60 M(+127.3%) |
| Dec 2020 | $8.18 M | -$7100.00(-100.1%) | $8.18 M(-53.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | $6.73 M(+611.6%) | $17.58 M(+62.3%) |
| Jun 2020 | - | $946.40 K(+86.3%) | $10.83 M(+9.7%) |
| Mar 2020 | - | $508.00 K(-94.6%) | $9.87 M(+5.6%) |
| Dec 2019 | $9.35 M(-4631.0%) | $9.39 M(<-9900.0%) | $9.35 M(-3902.8%) |
| Sep 2019 | - | -$13.30 K(+8.1%) | -$245.80 K(+5.7%) |
| Jun 2019 | - | -$12.30 K(-11.5%) | -$232.50 K(+5.6%) |
| Mar 2019 | - | -$13.90 K(-93.3%) | -$220.20 K(+6.7%) |
| Dec 2018 | -$206.30 K(-102.2%) | -$206.30 K(<-9900.0%) | -$206.30 K(-2163.0%) |
| Sep 2018 | - | $0.00(0.0%) | $10.00 K(-99.9%) |
| Jun 2018 | - | $0.00(0.0%) | $7.51 M(-12.1%) |
| Mar 2018 | - | $0.00(-100.0%) | $8.55 M(-10.4%) |
| Dec 2017 | $9.54 M(+655.4%) | $10.00 K(-99.9%) | $9.54 M(+0.1%) |
| Sep 2017 | - | $7.50 M(+624.8%) | $9.53 M(+370.4%) |
| Jun 2017 | - | $1.03 M(+4.5%) | $2.02 M(+104.5%) |
| Mar 2017 | - | $990.00 K | $990.00 K |
| Dec 2016 | $1.26 M | - | - |
FAQ
- What is Monopar Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Monopar Therapeutics?
- What is Monopar Therapeutics annual CFF year-on-year change?
- What is Monopar Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Monopar Therapeutics?
- What is Monopar Therapeutics quarterly CFF year-on-year change?
- What is Monopar Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Monopar Therapeutics?
- What is Monopar Therapeutics TTM CFF year-on-year change?
What is Monopar Therapeutics annual cash flow from financing activities?
The current annual CFF of MNPR is $2.03 M
What is the all time high annual CFF for Monopar Therapeutics?
Monopar Therapeutics all-time high annual cash flow from financing activities is $10.88 M
What is Monopar Therapeutics annual CFF year-on-year change?
Over the past year, MNPR annual cash flow from financing activities has changed by +$1.99 M (+6061.70%)
What is Monopar Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of MNPR is -$16.50 K
What is the all time high quarterly CFF for Monopar Therapeutics?
Monopar Therapeutics all-time high quarterly cash flow from financing activities is $10.92 M
What is Monopar Therapeutics quarterly CFF year-on-year change?
Over the past year, MNPR quarterly cash flow from financing activities has changed by -$3.20 M (-100.52%)
What is Monopar Therapeutics TTM cash flow from financing activities?
The current TTM CFF of MNPR is $3.49 M
What is the all time high TTM CFF for Monopar Therapeutics?
Monopar Therapeutics all-time high TTM cash flow from financing activities is $18.60 M
What is Monopar Therapeutics TTM CFF year-on-year change?
Over the past year, MNPR TTM cash flow from financing activities has changed by -$914.30 K (-20.76%)